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Abstract Rheumatoid arthritis (RA) is one of the most im-
portant rheumatic diseases. Its prevalence varies among ethnic
groups. Genetic and environmental factors influence its inci-
dence and prevalence. This chronic disease will increase its
frequency in the future due to population aging. The personal
impact of this disease on many relevant areas of an individual
requires special efforts to prevent and treat it properly. Ade-
quate advice on several recently described risk factors such as
tobacco and alcohol exposure, infections, obesity, and physi-
cal exercise should be part of every medical consultation. This
knowledge should be incorporated to improve health care pre-
vention programs. Patients and clinicians must work together
through better communication skills to finally improve out-
comes. Including RA in priority health care lists will need
special effort from rheumatology societies and better commu-
nication with policy makers.
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Rheumatoid arthritis (RA) is a chronic autoimmune disease of
unknown origin. Multiple factors have been proposed to inter-
act to produce a systemic disease that is characterized by joint
pain and swelling and a myriad of multiple manifestations
outside the joints. If not properly treated, this joint swelling will
produce damage and progressive disability. Life expectancy is
also diminished [1].
RA prevalence is around 1 % in the world but this number
changes in different ethnic populations. In Mexico, one study
using COPCORD methodology in 19,213 individuals, in five
different regions, found a global prevalence of 1.6 % with a
different prevalence rate ranging from 0.7% (95% confidence
interval (CI): 0.5–1.0) in Nuevo León to 2.8 % (95 % CI: 2.3–
3.3) in Yucatán [2]. In Luján, Argentina, a city of 70,000
inhabitants, a prevalence rate of 0.94 % (95 % CI: 0.86–
1.02 %) was found.
[3]. An interesting study recently done in 1656 Toba indi-
viduals living in Rosario, Argentina, found a prevalence of 2.4
(95 % CI: 1.7–3.2) [4]. These findings of increased preva-
lence in Yucatán, México, rich in original Mayan popula-
tion and in Toba population in Argentina have raised in-
creased interest in genetic, anthropologic, and environ-
mental factors in the development of RA in original pop-
ulations in our region. Multiple studies are currently un-
dergoing in several Latin American countries including
Argentina, Mexico, and Venezuela in an initiative called
GLADERPO (Grupo LAtinoamericano De Enfermedades
Reumáticas en Poblaciones Originales).
Incidence rates of RA are scarce in Latin America A re-
cently published study in Ontario in 97,499 Ontarians found a
cumulative prevalence of 0.9 %. Age- and sex-standardized
RA prevalence increased steadily over time from 473 (95 %
CI: 469–478) per 100,000 population (0.49 %) in 1996 to 784
(95 % CI: 779–789) per 100,000 population (0.9 %) in 2010.
Age- and sex-standardized incidence per 100,000 population
ranged from 62 (95 % CI: 60–63) in 1996 to 54 (95 % CI: 52–
55) in 2010 [5].
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RA is the prototype of chronic diseases It is very important
to be aware of multiple risk factors that have been described
and intervene in those that are modifiable in order to improve
patient outcomes. A brief description of the most commonly
cited and recently described is presented.
Genetics It is well recognized that rheumatoid arthritis has a
clear association with some genetic markers [6]. The shared
epitope is one of the most studied but there are other genes that
have been identified such as the PTPN22 [7]. Some protective
genes have been described in Chinese population fromTaiwan
[8]. Some new genes have been detected in Latin American
populations [9]. Although there have been important research
studies in this area, no direct clear benefit has been offered to
our patients with this knowledge yet. It is estimated that genes
do not explain the great majority of RA cases.
Environmental factors Intensive and active research has
been given to multiple environmental factors that have been
identified as associated with the development of rheumatoid
arthritis. The most studied have been hormonal, tobacco, al-
cohol, infections, toxic and pollutant agents, obesity, and
physical exercise. Updated information is presented.
Tobacco It has been established that tobacco is a risk factor for
RA development and particularly linked with a seropositive
disease [10]. It has been described that this association is
clearly related with genetic markers. Clinicians should be
aware of smoking habits in their patients, and cessation pro-
grams should be implemented. It has been suggested that RA
patients who continue smoking have less therapeutic clinical
response [11].
Alcohol Mild to moderate alcohol consumption has been as-
sociated with a protective effect on RA development when
compared to no or high alcohol consumption [12]. Some pos-
sible explanations have been offered, and immune modulation
and anti-inflammatory actions are the most plausible theories.
Although it is quite difficult to advise alcohol consumption,
clinicians could identify the potential benefit of a low to mod-
erate intake that seems to be particularly beneficial in women
in a recent meta-analysis [13].
Infections An increased interest in infections has gained rel-
evance in the last decade as a risk factor for RA development.
There is supporting evidence that Porphyromonas gingivalis
is associated with seropositive disease due to the citrullination
capabilities of this bacterium [14]. Some studies have also
shown that this association is related with disease activity
[15]. Increased interest in gut microbiome has gained intense
research attention in the last years in some diseases such as
RA, psoriasis, obesity, and metabolic syndrome. These
findings are quite promising since they offer clear practical
possibilities for therapeutic interventions.
Toxic and pollutants Some studies have identified increased
RA in some areas or human activities, where exposure to
pollutants has been described. This has been detected in urban
areas [16], exposure to insecticides [17], and also related to a
low socioeconomic status [18]. The explanation of this inter-
action has been proposed to be through epigenetic changes in
immune response genes. This piece of knowledge will be very
important to design possible reversibility of these genetic
modifications in the future. A clinician should be aware of this
and give proper advice to patients and their families.
Obesity This recently described risk factor [19] is very impor-
tant in Latin America when we are facing increasing obesity
problems even starting in childhood. It has been postulated
that obese subjects have an increased risk for RA develop-
ment, and obese subjects have a decreased chance to reach
remission or a low disease activity state [20]. Some data are
also available describing that obese subjects have a lower rate
of joint damage progression that has raised some possible
metabolic explanations [21]. This area of intervention is one
of the most important to be emphasized in a clinical setting.
Physical activity A recently published study described that
patients who have been physically active during the past
5 years previous to RA development had a milder disease
compared to those subjects who were sedentary [22] in terms
of disease activity, pain, and function. This information is
particularly useful to be taken into account in an appropriate
medical advice and public health recommendations.
Social and economic impact of rheumatoid arthritis
The increase in life expectancy has raised the frequency of
chronic musculoskeletal diseases, such as rheumatoid arthritis
(RA), and elevated treatment costs, generating global concern
for the last decade, which was declared as the Bdecade of bone
and joint^ by the World Health Organization. A statement
given by UN Secretary General Kofi Annan, declaring the
Bone and Joint Decade 2000–2010, 30 November 1999:
BMusculoskeletal disorders are the most common causes of
severe long term pain and physical disability, affecting many
millions of people across the globe. They have an enormous
impact on the individual, society, and health care social sys-
tems. There are effective ways to prevent or treat these dis-
abling conditions. But we must act on them now [23].^
RA is a chronic autoimmune disease that increases morbid-
ity, mortality, and produces high economic costs for the pa-
tient, the family, and society, besides altering the emotional
balance, thus altering the quality of life [24].
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Here are some necessary definitions of the costs to clearly
refer later:
Direct costs They are determined by the derivative of direct
patient care, like: medication, hospitalization, diagnostic or
therapeutic interventions, professional fees, transportation,
mechanical aids for the patient, physiotherapy, as well as nurs-
ing value.
Indirect costs Are those that come from paying disabilities.
Intangible costs They are difficult to estimate, since they
result from the reduction in earning capacity or decrease in
life expectancy [25, 26].
Without delving exhaustively, costs must be differentiated
before and after biologic agents, since these increased between
3–6 times and have moved hospitalization expenses as those
responsible for the high cost, as indicated by studies in the
USA and Europe [26, 27]. Michaud et al., in their cohort,
found a cost of US$6164/year when synthetic disease-
modifying antirheumatic drugs (DMARDs) are used, com-
pared to US$19,016/year with biologics [26]. A similar situa-
tion was observed in a French study [27]. However, with the
introduction of the combined therapy and biologics, we have
seen positive results, not only in the clinical aspect but also in
the indirect costs that are reflected in decreased hospital days,
decreased sick leave, and therefore, decrease of absenteeism,
with increased employment of patients, both men and women
[28, 29]. Another positive topic, as reported by Huscher et al.,
is that there is an absence of a steady increase in drug costs,
since it is estimated that, after 7 years, a plateau in the curve of
costs is reached by biologics [30]. But some doubts remain
regarding the possible success, as the sense of well-being and
the intensity of pain does not improve over time through a
decade [28].
Another relevant aspect is that there are factors of the same
disease that increase costs; for example, if the disease has a
duration of more or less than 6 months, significant differences
are established, with greater cost and with more disease dura-
tion, and the same phenomenon occurs with the number of
comorbidities [25]. With respect to HAQ, there is an exponen-
tial relationship, as a higher score implies higher costs, as
much as one point increase represents a cost of US$8084/year
[26, 31].
An indirect cost related to AR is the work stoppage. In a
study of 133 patients with 3 years of follow-up since the onset
of the disease, 78 (59 %) continued working, 23 (17 %) were
retired due to RA, 12 (9 %) lost their jobs but did not receive
pension, and 20 (15 %) were out of the workforce for reasons
other than RA causes [32].
In Latin America, there are few studies on costs in RA,
but they generally agree with the above (Table 1). A study
in Mexico by Ariza et al. indicates the lowest cost in the
region in relation to the exclusive use of synthetic
DMARDs [33]; along with the study of Buenogens et al.
[34], they are based on real-life patients. A Colombian
work, conducted by Mora et al., is a simulation study
and represents an important contribution that provides a
categorization based on disease activity, demonstrating
that high disease activity translates into increased direct
cost, fundamental basis in drug costs, becoming similar to
those of other first world countries [35].
Rheumatologist perspective
Undoubtedly, in recent decades, there has been a qualita-
tive change in the confrontation of RA, because, in the
first place, it was recognized as a severe disease that
turned the existing paradigm even in the second half of
the last century; this led to design strategies to achieve
earlier diagnosis, such as the development of early arthri-
tis clinics that have allowed us not only to distinguish RA
from other early inflammatory arthritis but also to recog-
nize patients with more aggressive disease, and, in con-
junction with the above statement, to set treatments ac-
cording to the aggressiveness, such as combination thera-
py with methotrexate as the cornerstone of treatment. Fi-
nally, the appearance of anti-TNF agents and other bio-
logics, which are similar to combination therapy, have
been a step forward in searching for a better disease con-
trol and, certainly, a better prognosis. We consider that the
establishment of new classification criteria for RA will
result in strengthening the possibility of an early diagnosis
of a serious disease.
Taking this into consideration has led a new positioning of
the rheumatologist as the leader of an interdisciplinary team
with greater strength, security, and optimism in his results. We
all hope that, in the nearest future, the cost of biologic agents
will decrease, and with the decrease of indirect and intangible
costs, these drugs will be more accessible for the general
population.
The above expectations are not free of any danger,
since the rheumatologist often feels pressure, not only
by health-care providers but also by the patients them-
selves, who, in their anxiety about their illness and knowl-
edgeable about the existence of biologic therapy, demand
for its early use, even without previous evaluation of syn-
thetic DMARDs. We think that their behavior is influ-
enced by the pharmaceutical industry.
Finally, we think that if we compare our current practice
with the past, the current scenario will contain much less frus-
tration and hopelessness than the one lived by rheumatologists
40 years ago, and, for patients, the future is safer, even in
countries like those in Latin America.
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Illness or disease? A life with rheumatoid arthritis:
the words from a patient
A large part of the cultural discord that exists between
patients and clinicians lies in the inherent difference be-
tween the patients’ subjective experience of Billness^
and the clinician’s objective approach to Bdisease^ [36].
We cannot start talking about the experience of living with
rheumatoid arthritis without taking some time to look at this
definition, written several years ago, but still so current. And
this is the case because it is not only a body that gets affected,
and it is not just a disease. Living with rheumatoid arthritis
means to experience deep transformations in different areas in
life: love, family, social life, job, to mention just a few; to live
the subjective experience of illness.
One of the narrations shared by patients with rheumatoid
arthritis concerns with some questions that arise after the di-
agnosis: why, why me, what did I do wrong? The attempt to
associate a traumatic event and the appearance of the first
symptoms is also recurrent, which somehow—true or not—
enables you to make sense of the transformation of the SELF
many of us go through. Already in the year 1981, Baron stat-
ed: Bpeople do not come in for diagnosis and treatment; they
come to be made well, made whole, to recover the sense of
health, of being well, fully alive, in-the-world [37].^
Readapting life is probably a term as valued by patients
with rheumatoid arthritis as remission, for being well, fully
alive implies a learning process, well summarized by this
young Chilean patient: Brheumatoid arthritis has given me
the gift of awareness to accept I am a vulnerable woman,
who feels and makes mistakes; courage to face my fears;
passion to live each day as if it was the last, understand life
is today and appreciate everything that shows up in my space;
gratitude to realize I have a wonderful family that takes care of
me, and gives me containment and support; and faith, because
I am certain that arthritis is just the symptom coming to show
me the unlearned lesson.^
Achieving a good re-adaptation or learning process de-
pends on at least five factors that we have been able to identify
working with these patients:
Access to treatment Latin America undergoes a very dissim-
ilar reality with regards to access to therapies. Nevertheless,
there is a common feeling concerning the financial decay gen-
erated by the difficulty to keep a steady job due to the symp-
tomatology of the disease. AnArgentinean young woman tells
it with a touch of humor that does not hide how dramatic this
situation is: BI don’t know what hurts more, my joints or the
fact that what I make is not enough to cover all my expenses.
Since I got sick, my financial situation worsened.^ Treatment
does not only imply medicine; treatment also means to have
an appropriate job, where you are still an active member of
society, physical therapy, and body re-education, among
others.
Social integration Counting on family, friends, or coworkers
who understand what you go through is comforting. Part of
the process each one goes through is that of accepting the new
limitations. If they have to be constantly hidden, this accep-
tance takes more than needed, thus delaying the re-learning
process. But the doubt that constantly arises is how to make
the other a part of an invisible pain that very often appears and
disappears with no explanation? The experience of chronic
pain affects the state of mind, and therefore, social
relationships.
Being recognized as Bexperts^ If we added up the hours we
spend with the clinical treating team, they would not add up to
more than a couple of days in a year. This condition is with us
on a daily basis. Therefore, certainly the ones who know better
than anyone else how it manifests, how it affects, or possible
ups and downs are the patients themselves. The fear to express
something experienced as reality very often affects the adher-
ence to any treatment and, above all, the self-management
Table 1 Comparison of costs in patients with rheumatoid arthritis in Latin America
Country/year Total direct costs US$ Drug costs (%) Medical costs (%) Other costs (%) Synthetic DMARDs Biologic agents
Mexico 2005 (12) 1735 25.76 51.33 22.9 Yes Do not
Brazil 2008 (13) 14,185 90.8 6.8 2.4 Yes Yes
Colombia 2009 (14) 1,689–23,441a 86 14 – Yes Yes
a Depending on the rate of activity of the AR
Table 2 Patient and clinician share expertise
Patient Clinician
Expertise of illness Diagnosis
Social circumstances Disease etiology
Attitude to risk Prognosis
Values Treatment options
Preferences Outcome probabilities
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process that every person living with a chronic condition
requires. As defined by Angela Coulter, it is necessary to
learn about sharing expertise [37] and summarized in
Table 2. Understanding and respecting everybody’s scope
of action enables the movement towards a healthier and stron-
ger physician-patient relationship. Expert patients are Bpeople
who have the confidence, skills, information, and knowledge
to play a central role in the management of life with chronic
diseases and to minimize the impact of disease on their lives^
[38].
First-hand quality information Making decisions dealing
with one’s own health and life in general is a process whose
frequency and motivation very often depend on how rooted this
practice is within one’s own culture. When it comes to ap-
proaching chronic diseases, this is a central process of self-man-
agement.Making decisions requires having the best information
available. Most of the time, the patient expects that information
to be given by someone in the groupwhere they put their trust: a
member of their clinical team. Patients’ and clinicians’ commu-
nication skills are critical to pushing forward with this process,
so as to select everything that is important, but at the same time,
present it in a way that the other can understand.
Peer support and social networking The great need to rely
on people who understands the process that you are going
through has led in recent years to a sharp rise in the amount of
social networks available for patients with rheumatoid arthritis.
In these virtual groups, not only the support and understanding
very often required are found but also experiences regarding the
disease are shared, which enable better management. Neverthe-
less, without a clear understanding of what role each of them
plays in the process, situations can come up in which among
patients there are recommendations on what drugs or dosage to
use. Once again, a good partnership between physicians and
patients can build a better virtual space. Living a life with
rheumatoid arthritis is a life in which you have to take charge
of an illness and a disease, and to do so, a strong partnership
between clinicians and patients is undoubtedly the best strategy.
An integrated approach to rheumatoid arthritis requires not
only substantial improvements in public policies in each of our
countries but also progress in the clinician-patient relationship
towards informed, shared decision-making and patient-
centered care. We know it is a long way, but we want to be a
part of it. Let us help!1
Rheumatoid arthritis and priority health problems
Rheumatic diseases represent a complex group of health prob-
lems that produce diverse degrees of pain, suffering, disability,
and poor quality of life. If not properly treated a decreased
survival is also detected [1].
Rheumatologists have been struggling for many years in
different health care environments to improve patient care. Lat-
in America has important challenges in terms of epidemiologic
transition. Our region still has multiple health-care needs that
are common to developing countries such as maternal and
health-care problems, infections, addictions, violence and at
the same time they need to provide adequate care to chronic
diseases commonly seen in developed countries such as obesi-
ty, diabetes, hypertension, cancer, and rheumatic diseases. A
recently published survey on global disability found that RA
was ranked as the 42nd highest contributor to global disability,
just below malaria and just above iodine deficiency [38].
Health-care budgets need to establish priorities that take
into account several approaches [39]. Exclusion of rheumatic
diseases is a common finding in these exercises since burden
of illness is frequently taken into account and the low preva-
lence of RA does not compete with other large health-care
problems such as hypertension, type 2 diabetes mellitus, mal-
nutrition, and maternal health. Other criteria that include pre-
ventive interventions and cost-effective interventions are not
easily justified to reach a priority.
Political issues dominate some decisions, and rheumatolo-
gy societies have not delivered yet solid local information to
be used by policy makers.
Smart strategies should be proposed to gather more and
better knowledge, incorporate the concept of quality of life
in a multi dimensional concept decision process. Rheumatol-
ogy societies should be part of teams of decision makers and
plan organized strategies that need to be consistent with the
final ideal of better health from a societal perspective.
Rheumatologists need to be aware that adequate clinical
and therapeutic decisions should always take into account
the rational use of resources in our patients in the context of
societies looking for equity.
Regional decisions should try to produce better outcomes
using optimized strategies in our patients. Rheumatologists
have a great potential to change this perspective that leaves
out rheumatoid arthritis and other rheumatic diseases from
priority health list in the region, by performing coherent ac-
tivities to positively change health care of rheumatic patients
in Latin America.
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1 Let us help! is inspired byDavid deBronkart’s quote BPlease,
let patients help improve healthcare. Let patients help steer our
decisions, strategic and practical. Let patients help define what
value in medicine is.^
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